Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk: Buy Hand Over Fist While Others Panic
Novo Nordisk remains a Strong Buy despite a 20% stock decline following disappointing CagriSema trial results versus Eli Lilly's tirzepatide. NVO's valuation is compelling, with a P/E of 10.42 and FCF yield above 5.2%, while its dividend yield has reached a decade high of ~4.9%. Strategic pivots include a promising triple G agonist (UBT251), a digital partnership with Hims, and pipeline expansion into MASH and heart failure.
Game Creek Capital LP Purchases New Position in Novo Nordisk A/S $NVO
Game Creek Capital LP acquired a new stake in Novo Nordisk A/S (NYSE: NVO) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,250 shares of the company's stock, valued at approximately $1,290,000. A number of other hedge funds and
3 Dirt-Cheap Stocks to Buy With $1,000 Right Now
Investors are understandably fearful that Uber Technologies' profits are going to be under a growing degree of pressure. Insurer Progressive's outstanding 2025 results were too good to last.
Novo Nordisk A/S $NVO Stock Position Decreased by Bank of Montreal Can
Bank of Montreal Can cut its stake in shares of Novo Nordisk A/S (NYSE: NVO) by 57.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,057,418 shares of the company's stock after selling 1,417,882 shares during the period. Bank of Montreal Can's
Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Novo Nordisk (NVO) closed the most recent trading day at $38.02, moving 2.09% from the previous trading session.
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health NYSE: HIMS is making headlines as shares are surging in the wake of an agreement with GLP-1 maker Novo Nordisk NYSE: NVO—the very company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9.
Novo Nordisk: Buying The Dip Before Volume Dominance
Novo beat Q4 consensus on revenue and adjusted EPS, driven by 31% obesity-care growth, yet shares fell nearly 40% after a shocking FY2026 guidance cut. Gross margin compressed as D&A and integration costs rose, while higher R&D and administrative expenses pushed EBIT margin down 290 basis points, pressuring earnings momentum. Management guided FY2026 sales decline of 5-13%, citing U.S. price pressure, MFN impacts, LOE effects, and mix shifts outweighing planned volume growth.
Hims & Hers stock: why today's gains are unlikely to be sustainable
Hims & Hers Health Inc (NYSE: HIMS) soared nearly 50% this morning after announcing a landmark settlement and partnership with the Danish pharma giant – Novo Nordisk (NYSE: NVO). This meteoric run erased losses triggered by last month's patent litigation, but HIMS stock remains down some 38% versus its year-to-date high.
Hims & Hers stock price is surging today. A surprising deal with Novo Nordisk is the reason why
Shares in Hims & Hers Health (NYSE: HIMS) are soaring this morning after a report that the telehealth company is entering into a deal with Novo Nordisk A/S (NYSE: NVO) to sell its popular GLP-1 weight-loss drugs, including Wegovy.
Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute
Novo Nordisk (NYSE:NVO)and US telehealth company Hims & Hers (NYSE:HIMS) have announced a collaboration that will bring the Danish drugmaker's weight-loss medications Wegovy and Ozempic to Hims & Hers' platform, ending a recent legal dispute between the two companies. The partnership marks a shift in strategy for Hims & Hers, which will now provide US customers access to a broad assortment of FDA-approved GLP-1 treatments, including semaglutide injections and tablets at various dosages.
NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell?
Novo Nordisk erases most gains since Wegovy's 2021 launch as Lilly's drugs outperform its therapies in clinical studies and price cuts loom across its core GLP-1 franchise.
Novo's Quiet Comeback Begins
Novo Nordisk ended its dispute with Hims & Hers Health, enabling Wegovy distribution across a digital platform serving roughly 2.5 million subscribers. Novo Nordisk maintains exceptional profitability with an 82.41% gross margin and 45.50% EBIT margin, significantly exceeding sector medians. FY25 net profit reached DKK 100 billion while operating cash flow approached DKK 120 billion, supporting major CapEx, acquisitions, and shareholder returns.
